Scott Bizily - Apr 16, 2024 Form 4 Insider Report for 4D Molecular Therapeutics, Inc. (FDMT)

Signature
By: /s/ Scott Bizily
Stock symbol
FDMT
Transactions as of
Apr 16, 2024
Transactions value $
-$31,750
Form type
4
Date filed
4/18/2024, 08:48 PM
Previous filing
Apr 3, 2024
Next filing
May 20, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FDMT Common Stock Options Exercise $3.25K +500 +28.79% $6.49 2.24K Apr 16, 2024 Direct F1
transaction FDMT Common Stock Options Exercise $10.1K +1.25K +55.88% $8.04 3.49K Apr 16, 2024 Direct F1
transaction FDMT Common Stock Sale -$45K -1.75K -50.19% $25.74 1.74K Apr 16, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FDMT Stock Option (Right To Buy) Options Exercise $0 -500 -3.4% $0.00 14.2K Apr 16, 2024 Common Stock 500 $6.49 Direct F1, F2
transaction FDMT Stock Option (Right To Buy) Options Exercise $0 -1.25K -3.09% $0.00 39.2K Apr 16, 2024 Common Stock 1.25K $8.04 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023.
F2 The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of June 16, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.
F3 The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of September 1, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.